Literature DB >> 27551134

Biomarkers for Early-Stage Breast Cancer: Clinical Utility for Extended Adjuvant Treatment Decisions.

Dennis C Sgroi1, Adam Brufsky1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27551134     DOI： 10.1200/JCO.2016.67.2949

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  2 in total

1.  Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events.

Authors:  Tobias Meißner; Adam Mark; Casey Williams; Wolfgang E Berdel; Stephanie Wiebe; Andrea Kerkhoff; Eva Wardelmann; Timo Gaiser; Carsten Müller-Tidow; Philip Rosenstiel; Norbert Arnold; Brian Leyland-Jones; Andre Franke; Martin Stanulla; Michael Forster
Journal:  Cold Spring Harb Mol Case Stud       Date:  2017-07-05

2.  Can Histological Grade and Mitotic Index Replace Ki67 to Determine Luminal Breast Cancer Subtypes?

Authors:  David Oddó; Dahiana Pulgar; Nicole Elgueta; Francisco Acevedo; Dravna Razmiliz; María Elena Navarro; Mauricio Camus; Tomás Merino; Ignacio Retamal; Alejandra Pérez-Sepúlveda; Alejandra Villarroel; Héctor Galindo; José Peña; César Sánchez
Journal:  Asian Pac J Cancer Prev       Date:  2018-01-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.